(Q51294468)

2 April 2018

editorial

0 references

review article

1 reference

title

Co-stimulatory blockade with belatacept in kidney transplantation. (English)

1 reference

2 April 2018

author name string

Bhavna Chopra

series ordinal

1

1 reference

2 April 2018

Kalathil K Sureshkumar

series ordinal

2

1 reference

2 April 2018

language of work or name

English

0 references

publication date

12 March 2014

1 reference

2 April 2018

Expert Opinion on Biological Therapy

published in

1 reference

2 April 2018

volume

14

1 reference

2 April 2018

issue

5

1 reference

2 April 2018

page(s)

563-567

1 reference

2 April 2018

Long-term renal allograft survival in the United States: a critical reappraisal

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Logistics and strategy of multiorgan procurement involving total face allograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

T-cell co-stimulatory blockade in transplantation: two steps forward one step back!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.896332

10.1517/14712598.2014.896332

21 January 2018

Identifiers

DOI

1 reference

2 April 2018

PubMed ID

24620724

1 reference

2 April 2018